159 related articles for article (PubMed ID: 30103709)
1. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
Tosi D; Pérez-Gracia E; Atis S; Vié N; Combès E; Gabanou M; Larbouret C; Jarlier M; Mollevi C; Torro A; Del Rio M; Martineau P; Gongora C
BMC Cancer; 2018 Aug; 18(1):812. PubMed ID: 30103709
[TBL] [Abstract][Full Text] [Related]
2. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Mueller A; Bachmann E; Linnig M; Khillimberger K; Schimanski CC; Galle PR; Moehler M
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1601-15. PubMed ID: 22543857
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.
Jin L; Jin MH; Nam AR; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Lett; 2017 Dec; 411():162-170. PubMed ID: 29024814
[TBL] [Abstract][Full Text] [Related]
6. The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
Yu F; Zhao J; Hu Y; Zhou Y; Guo R; Bai J; Zhang S; Zhang H; Zhang J
Oncol Rep; 2016 Jul; 36(1):356-64. PubMed ID: 27175939
[TBL] [Abstract][Full Text] [Related]
7. Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer.
Clarke PA; Roe T; Swabey K; Hobbs SM; McAndrew C; Tomlin K; Westwood I; Burke R; van Montfort R; Workman P
Oncogene; 2019 Jun; 38(25):5076-5090. PubMed ID: 30905967
[TBL] [Abstract][Full Text] [Related]
8. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
Signore M; Buccarelli M; Pilozzi E; De Luca G; Cappellari M; Fanciulli M; Goeman F; Melucci E; Biffoni M; Ricci-Vitiani L
Oncotarget; 2016 Jul; 7(28):44113-44128. PubMed ID: 27286453
[TBL] [Abstract][Full Text] [Related]
9. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
Hochster HS; Uboha N; Messersmith W; Gold PJ; ONeil BH; Cohen D; Denlinger C; Cohen S; Leichman CG; Leichman L; Lenz HJ
Cancer Chemother Pharmacol; 2015 Jan; 75(1):17-23. PubMed ID: 25322874
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
12. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
[TBL] [Abstract][Full Text] [Related]
13. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
Mazard T; Causse A; Simony J; Leconet W; Vezzio-Vie N; Torro A; Jarlier M; Evrard A; Del Rio M; Assenat E; Martineau P; Ychou M; Robert B; Gongora C
Mol Cancer Ther; 2013 Oct; 12(10):2121-34. PubMed ID: 23960095
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
17. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
Shelton JW; Waxweiler TV; Landry J; Gao H; Xu Y; Wang L; El-Rayes B; Shu HK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):469-76. PubMed ID: 23540347
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.
Yamaguchi T; Kakefuda R; Tajima N; Sowa Y; Sakai T
Int J Oncol; 2011 Jul; 39(1):23-31. PubMed ID: 21523318
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.
Haagensen EJ; Thomas HD; Schmalix WA; Payne AC; Kevorkian L; Allen RA; Bevan P; Maxwell RJ; Newell DR
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1269-1281. PubMed ID: 27837257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]